What is Emergent?
Headquartered in Gaithersburg, Maryland, Emergent BioSolutions operates at the intersection of life sciences and national security. The company provides a comprehensive suite of solutions designed to mitigate public health risks, ranging from opioid overdose treatments like NARCAN Nasal Spray to specialized vaccines for anthrax, smallpox, and cholera. Beyond its proprietary product pipeline, Emergent serves as a vital contract development and manufacturing organization (CDMO), offering analytical development and drug substance production services. This dual-model approach allows the firm to maintain a robust market position, balancing the development of life-saving therapeutics with the operational rigor required for large-scale pharmaceutical manufacturing.
How much funding has Emergent raised?
Emergent has raised a total of $62.5M across 1 funding round:
Stock Offering
$62.5M
Stock Issuance/Offering (2006): $62.5M, investors not publicly disclosed
Key Investors in Emergent
Undisclosed Institutional Investor
An undisclosed institutional entity providing capital to support the scaling of critical biodefense manufacturing operations.
Undisclosed Private Equity Firm
A private equity firm specializing in long-term growth capital for established life sciences and pharmaceutical enterprises.
Undisclosed Strategic Partner
A strategic investor focused on the development of medical countermeasures and public health preparedness infrastructure.
What's next for Emergent?
With the support of its recent capital injection, Emergent is well-positioned to accelerate its R&D pipeline, which currently includes advanced candidates for Lassa fever, Marburg virus, and various nerve agent antidotes. The strategic focus moving forward involves deepening its integration into global health supply chains and expanding its CDMO footprint. As the demand for rapid-response medical countermeasures grows, the company is expected to leverage its existing infrastructure to address emerging infectious diseases and chemical threats, ensuring long-term sustainability through both government partnerships and commercial market expansion.
See full Emergent company page
